vs
林德(LIN)与礼来(RNA)财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是林德的1.4倍($12.5M vs $8.8M),礼来同比增速更快(434.0% vs 8.2%),林德自由现金流更多($898.0K vs $-156.9M),过去两年礼来的营收复合增速更高(138.5% vs -96.7%)
林德是全球知名跨国化工企业,按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立,现总部位于英国沃金,在爱尔兰注册,2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业,在18个国家设有办事处,产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立,品牌名即取自创始人姓名。
LIN vs RNA — 直观对比
营收规模更大
RNA
是对方的1.4倍
$8.8M
营收增速更快
RNA
高出425.8%
8.2%
自由现金流更多
LIN
多$157.8M
$-156.9M
两年增速更快
RNA
近两年复合增速
-96.7%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $8.8M | $12.5M |
| 净利润 | — | $-174.4M |
| 毛利率 | 48.5% | — |
| 营业利润率 | 27.8% | -1513.5% |
| 净利率 | — | -1398.3% |
| 营收同比 | 8.2% | 434.0% |
| 净利润同比 | — | -117.0% |
| 每股收益(稀释后) | $3.98 | $-1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
LIN
RNA
| Q1 26 | $8.8M | — | ||
| Q4 25 | $8.8B | — | ||
| Q3 25 | $8.6B | $12.5M | ||
| Q2 25 | $8.5B | $3.8M | ||
| Q1 25 | $8.1B | $1.6M | ||
| Q4 24 | $8.3B | $3.0M | ||
| Q3 24 | $8.4B | $2.3M | ||
| Q2 24 | $8.3B | $2.0M |
净利润
LIN
RNA
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.9B | $-174.4M | ||
| Q2 25 | $1.8B | $-157.3M | ||
| Q1 25 | $1.7B | $-115.8M | ||
| Q4 24 | $1.7B | $-102.3M | ||
| Q3 24 | $1.6B | $-80.4M | ||
| Q2 24 | $1.7B | $-70.8M |
毛利率
LIN
RNA
| Q1 26 | 48.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率
LIN
RNA
| Q1 26 | 27.8% | — | ||
| Q4 25 | 23.0% | — | ||
| Q3 25 | 27.5% | -1513.5% | ||
| Q2 25 | 27.7% | -4448.7% | ||
| Q1 25 | 26.9% | -8360.9% | ||
| Q4 24 | 27.4% | -4069.6% | ||
| Q3 24 | 25.0% | -4200.9% | ||
| Q2 24 | 26.4% | -4040.4% |
净利率
LIN
RNA
| Q1 26 | — | — | ||
| Q4 25 | 17.5% | — | ||
| Q3 25 | 22.4% | -1398.3% | ||
| Q2 25 | 20.8% | -4089.3% | ||
| Q1 25 | 20.6% | -7360.0% | ||
| Q4 24 | 20.8% | -3439.5% | ||
| Q3 24 | 18.5% | -3441.7% | ||
| Q2 24 | 20.1% | -3461.8% |
每股收益(稀释后)
LIN
RNA
| Q1 26 | $3.98 | — | ||
| Q4 25 | $3.28 | — | ||
| Q3 25 | $4.09 | $-1.27 | ||
| Q2 25 | $3.73 | $-1.21 | ||
| Q1 25 | $3.51 | $-0.90 | ||
| Q4 24 | $3.61 | $-0.80 | ||
| Q3 24 | $3.22 | $-0.65 | ||
| Q2 24 | $3.44 | $-0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $4.0M | $350.2M |
| 总债务越低越好 | $24.7M | — |
| 股东权益账面价值 | $40.1M | $1.9B |
| 总资产 | $86.3M | $2.1B |
| 负债/权益比越低杠杆越低 | 0.62× | — |
8季度趋势,按日历期对齐
现金及短期投资
LIN
RNA
| Q1 26 | $4.0M | — | ||
| Q4 25 | $5.1B | — | ||
| Q3 25 | $4.5B | $350.2M | ||
| Q2 25 | $4.8B | $243.9M | ||
| Q1 25 | $5.3B | $254.2M | ||
| Q4 24 | $4.8B | $219.9M | ||
| Q3 24 | $5.2B | $370.2M | ||
| Q2 24 | $4.6B | $575.8M |
总债务
LIN
RNA
| Q1 26 | $24.7M | — | ||
| Q4 25 | $20.7B | — | ||
| Q3 25 | $18.6B | — | ||
| Q2 25 | $19.7B | — | ||
| Q1 25 | $17.6B | — | ||
| Q4 24 | $15.3B | — | ||
| Q3 24 | $17.5B | — | ||
| Q2 24 | $16.9B | — |
股东权益
LIN
RNA
| Q1 26 | $40.1M | — | ||
| Q4 25 | $38.2B | — | ||
| Q3 25 | $38.6B | $1.9B | ||
| Q2 25 | $38.5B | $1.2B | ||
| Q1 25 | $38.0B | $1.3B | ||
| Q4 24 | $38.1B | $1.4B | ||
| Q3 24 | $39.2B | $1.5B | ||
| Q2 24 | $38.2B | $1.2B |
总资产
LIN
RNA
| Q1 26 | $86.3M | — | ||
| Q4 25 | $86.8B | — | ||
| Q3 25 | $86.0B | $2.1B | ||
| Q2 25 | $86.1B | $1.4B | ||
| Q1 25 | $82.7B | $1.5B | ||
| Q4 24 | $80.1B | $1.6B | ||
| Q3 24 | $82.5B | $1.6B | ||
| Q2 24 | $80.2B | $1.3B |
负债/权益比
LIN
RNA
| Q1 26 | 0.62× | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | — | $-156.2M |
| 自由现金流经营现金流 - 资本支出 | $898.0K | $-156.9M |
| 自由现金流率自由现金流/营收 | 10.2% | -1257.6% |
| 资本支出强度资本支出/营收 | — | 5.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $4.2B | $-592.3M |
8季度趋势,按日历期对齐
经营现金流
LIN
RNA
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.9B | $-156.2M | ||
| Q2 25 | $2.2B | $-199.7M | ||
| Q1 25 | $2.2B | $-124.8M | ||
| Q4 24 | $2.8B | $-99.9M | ||
| Q3 24 | $2.7B | $-65.6M | ||
| Q2 24 | $1.9B | $-65.0M |
自由现金流
LIN
RNA
| Q1 26 | $898.0K | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $-156.9M | ||
| Q2 25 | $954.0M | $-203.0M | ||
| Q1 25 | $891.0M | $-128.6M | ||
| Q4 24 | $1.6B | $-103.8M | ||
| Q3 24 | $1.7B | $-67.3M | ||
| Q2 24 | $796.0M | $-65.5M |
自由现金流率
LIN
RNA
| Q1 26 | 10.2% | — | ||
| Q4 25 | 17.9% | — | ||
| Q3 25 | 19.4% | -1257.6% | ||
| Q2 25 | 11.2% | -5277.1% | ||
| Q1 25 | 11.0% | -8174.3% | ||
| Q4 24 | 18.8% | -3491.0% | ||
| Q3 24 | 19.9% | -2881.8% | ||
| Q2 24 | 9.6% | -3204.6% |
资本支出强度
LIN
RNA
| Q1 26 | — | — | ||
| Q4 25 | 16.6% | — | ||
| Q3 25 | 14.8% | 5.7% | ||
| Q2 25 | 14.8% | 86.9% | ||
| Q1 25 | 15.7% | 238.6% | ||
| Q4 24 | 15.1% | 131.7% | ||
| Q3 24 | 12.8% | 72.9% | ||
| Q2 24 | 13.7% | 26.0% |
现金转化率
LIN
RNA
| Q1 26 | — | — | ||
| Q4 25 | 1.98× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.76× | — | ||
| Q2 24 | 1.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图